New consultation: CRG actions June 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2024 CRG meeting. Actions in this consultation include:

  • Sunscreens for ACBS conditions – discontinued products to be removed from formulary and replaced with Anthelios SPF 50+ lotion (first choice) and Uvistat Suncream SPF 50 (alternative)
  • Remdesivir and tixagevimab plus cilgavimab – RED
  • Atogepant for treating migraine – Green (specialist advice)
  • Setmelanotide – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.


Decisions approved by GM ICB Executive – May 2024

The decisions made at the Greater Manchester Medicines Management Group (GMMMG) May 2024 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in May 2024 and NICE Technology appraisals published in January 2024.

The following decisions were approved and can be found at:

Colleagues are asked disseminate for implementation within your organisations.

All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.


GMMMG updates – May 2024

Following the May meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website:

Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the formulary change log available on the formulary page.


Seven minute briefings

The GMMMG Medicines Safety Subgroup has produced a new series of 7 minute briefings. These pieces are intended to facilitate shared learning regarding medicines, particularly where there are cross-sector implications.

The first topics have now been approved by CEGC, and are available on a dedicated page of the GMMMG site. They are:

  • Cyclizine dependency
  • Nitrofurantoin: pulmonary and hepatic adverse drug reactions
  • Tramadol and warfarin interaction

All of these topics, and any future ones, are available on the 7 minute briefings page of the site.


Decisions approved by GM ICB Executive – April 2024

The decisions made at the Greater Manchester Medicines Management Group (GMMMG) April 2024 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in April 2024 and NICE Technology appraisals published in December 2023.

The following decisions were approved and can be found at:

Colleagues are asked disseminate for implementation within your organisations.

All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.


New consultation: CRG actions May 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2024 CRG meeting. Actions in this consultation include:

  • Levomepromazine 6.25mg tablets – green, alternative option where small doses are required and tablet splitting is not appropriate
  • Phenobarbital 15mg/5ml elixir – green (specialist advice) and grey (criterion 1), only for select adult patients for whom ethanol consumption is safe and appropriate. Not for use in children.
  • Bowl cleansing preparations – red, and product list updated to Plenvu, sodium picosulfate with magnesium citrate, and Klean-Prep
  • FreeStyle Libre 2 plus and Dexcom One plus – add as additional options for new and existing patients

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.


New consultation: communication standards for opioid medicines prescribed at discharge

On behalf of the GMMMG Medicines Safety Group, we now seek comments on draft Communication Standards for Opioid Medicines Prescribed at Discharge.

The draft document has been developed to support safe prescribing of opioids by improving and standardising the information communicated from secondary care to primary care when patients are discharged from hospital with an opioid medicine for pain management. The document has been developed by a task and finish group on behalf of the GM Medicines Safety Group. The document has been reviewed by members of the task and finish group, Medicines Safety Group, and has been circulated via the chief pharmacists group for comments.

This consultation will run for six weeks and closes at 5pm on Thursday 27th June 2024. To take part, visit the consultations page.


GMMMG updates – April 2024

Following the April meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website:

  • Shared care protocols for amiodarone and dronedarone published; see full list of shared care protocols.
  • FreeStyle Libre 3 – added to RAG list as RED
  • Levonorgestrel 20 micrograms / 24 hours intrauterine delivery system (Benilexa) – added as a first-line option alongside Kyleena, Levosert, and Mirena.
  • Secukinumab for hidradenitis suppurativa – added as RED
  • Velmanase alfa – added as RED

Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the formulary change log available on the formulary page.


New consultation: CRG actions April 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2024 CRG meeting. Actions in this consultation include:

  • Lamotrigine tablets – green specialist advice for bipolar disorder
  • Doxylamine / pyridoxine for nausea and vomiting in pregnancy – removed from grey list and made a first choice option alongside cyclizine and prochlorperazine
  • Levemir InnoLet and Insulatard InnoLet – remove from formulary following discontinuation of the products
  • Buprenorphine prolonged release solution for injection (Buvidal) – add to formulary as alternative to methadone and oral buprenorphine
  • Fluocinolone intravitreal implant – RED
  • Dupilumab for prurigo nodularis – DNP
  • Etrasimod for ulcerative colitis – RED
  • Ritlecitinib for alopecia areata – RED
  • Satralizumab for neuromyelitis optica spectrum disorders – DNP
  • Sebelipase alfa for lysosomal acid lipase deficiency – DNP

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 24th May 2024. To take part, visit the consultations page.


Decisions approved by GM ICB Executive – March 2024

The decisions made at the Greater Manchester Medicines Management Group (GMMMG) March 2024 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in March 2024 and NICE Technology appraisals published in November 2023.

The following decisions were approved and can be found at:

Colleagues are asked disseminate for implementation within your organisations.

Drugs with a NICE recommendation published in December 2023 have been considered by CRG at its March 2024 meeting, and will be considered for approval by GMMMG and CEGC at their April 2024 meetings.

All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.